Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589624 · ClinicalTrials.gov registry record · Phase 1
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
A Phase 1 study of Thyroid Gland Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04589624 is a Phase 1 study of Thyroid Gland Carcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants, below the 783-participant average among 3 other Thyroid Gland Carcinoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04589624, a Phase 1 study of Thyroid Gland Carcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging
- DRUG Hyperpolarized Carbon C 13 Pyruvate
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-08-12 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04589624
The ClinicalTrials.gov registry entry for NCT04589624 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 783-participant average among 3 other Thyroid Gland Carcinoma trials with a reported enrollment target (95% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Gland Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging is the first listed.
NCT04589624 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04589624 about?
NCT04589624 is a clinical study titled "An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy". This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer and other malignancies of the head and neck undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI ...
What is the current status of trial NCT04589624?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-08-12. Estimated completion is 2027-05-31.
What conditions does trial NCT04589624 study?
This clinical trial studies the following conditions: Thyroid Gland Carcinoma.
What interventions are being tested in trial NCT04589624?
The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Hyperpolarized Carbon C 13 Pyruvate (DRUG).
Who is sponsoring clinical trial NCT04589624?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04589624 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Gland Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer
RECRUITING
-
Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters
RECRUITING
-
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.